Drug Information

General Information
Drug ID
DR00193
Drug Name
Tamoxifen
Synonyms
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Citofen; Crisafeno; Diemon; Gen-Tamoxifen; Istubal (TN); Istubol; Nolvadex (TN); Nolvadex-D; Nourytam; Novaldex; Novo-Tamoxifen; Oncomox; Pms-Tamoxifen; Retaxim; TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); TRANS FORM OF TAMOXIFEN; Tamizam; Tamone; Tamoplex (TN); Tamoxen; Tamoxifen (Hormonal therapy); Tamoxifen (INN); Tamoxifen (TN); Tamoxifen (Z); Tamoxifen [INN:BAN]; Tamoxifen and its salts; Tamoxifene; Tamoxifene [INN-French]; Tamoxifeno [INN-Spanish]; Tamoxifeno;Tamoxifenum; Tamoxifenum [INN-Latin]; Tomaxithen; Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; Trans-Tamoxifen; Valodex; Valodex (TN)
Drug Type
Small molecular drug
Indication Breast cancer [ICD11:2C60-2C6Z] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C26H29NO
Canonical SMILES
CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
InChI
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
InChIKey
NKANXQFJJICGDU-QPLCGJKRSA-N
CAS Number
CAS 10540-29-1
Pharmaceutical Properties Molecular Weight 371.5 Topological Polar Surface Area 12.5
Heavy Atom Count 28 Rotatable Bond Count 8
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 2
XLogP
7.1
PubChem CID
2733526
PubChem SID
11113844 ,14853108 ,24900307 ,26697206 ,26752017 ,26752018 ,30091348 ,4266414 ,46393636 ,46487938 ,46505515 ,47213210 ,47216564 ,47364953 ,47364954 ,47364955 ,47588786 ,47662047 ,47662048 ,47662049 ,47736233 ,47959503 ,48184778 ,48258990 ,48334237 ,48427434 ,49688681 ,49698369 ,49854602 ,50104683 ,50104684 ,50104685 ,50104686 ,53789476 ,56310641 ,56310662 ,56310717 ,56310801 ,56311275 ,56311294 ,56311693 ,56311998 ,56312239 ,56312443 ,56312444 ,603542 ,7886804 ,7980727 ,8794645 ,9319
ChEBI ID
ChEBI:41774
TTD Drug ID
D07KSG
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP7 Transporter Info Multidrug resistance-associated protein 7 Substrate [3]
P-GP Transporter Info P-glycoprotein 1 Substrate [4]
Drug-Transporter Activity Data
Drug-Transporter Activity Data MRP7 Transporter Info Km =0.078 microM LLC-PK1 cells-MRP7 [3]
References
1 Tamoxifen was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
3 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.